ChitogenX Competitors

OTC Stocks . USA . 
Stock . ChitogenX
CHNXF Stock  USD 0.01  0.0001  1.96%   
ChitogenX competes with Cellectis, Lipella Pharmaceuticals, Senti Biosciences, Fennec Pharmaceuticals, and Monopar Therapeutics; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing ChitogenX competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ChitogenX to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out ChitogenX Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ChitogenX competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ChitogenX's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.017.93
Details
Intrinsic
Valuation
LowRealHigh
0.0007.92
Details
Naive
Forecast
LowNextHigh
0.00008307.92
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
00.010.01
Details

ChitogenX Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ChitogenX and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of ChitogenX and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ChitogenX does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
BIOAF
+ 1.0
APTCF
MYMX
+ 1.0
APTCF
MYMX
+ 1.0
BIOAF
TCDAQ
+ 0.79
STAB
TCDAQ
+ 0.5
PKTX
STAB
+ 0.41
PKTX
  
High negative correlations   
PKTX
- 0.6
CRPOF
TCDAQ
- 0.56
CRPOF
CRPOF
- 0.49
BITRF
STAB
- 0.33
CRPOF
STAB
- 0.11
BITRF
CDAKQ
- 0.0
TCDAQ

Risk-Adjusted Indicators

There is a big difference between ChitogenX OTC Stock performing well and ChitogenX OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ChitogenX's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
APTCF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CMVLF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
BITRF  3.09 (0.73) 0.00  0.43  0.00 
 0.00 
 1.34 
(5.84)
 62.53 
BIOAF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CRPOF  123.42  56.87  8.56  1.12  0.00 
(248.97)
 10.53 
(8.37)
 4,159 
MYMX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
PKTX  9.47  0.82  0.03 (0.16) 11.80 
(13.54)
 25.00 
(20.71)
 84.38 
STAB  7.55 (1.04) 0.00 (1.21) 0.00 
 0.00 
 16.13 
(16.99)
 64.44 
TCDAQ  7.99 (2.59) 0.00  2.60  0.00 
 0.00 
 13.33 
(16.33)
 76.06 
CDAKQ  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
All Fundamental Data

ChitogenX Competitive Analysis

The better you understand ChitogenX competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ChitogenX's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ChitogenX's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CHNXF APTCF CMVLF BITRF BIOAF CRPOF MYMX PKTX STAB TCDAQ
 1.96 
 0.01 
ChitogenX
 0.00 
 0.0002 
Advanced
 0.00 
 2.54 
Cellectis
 16.67 
 0.01 
Biotron
 0.00 
 0.0001 
BiOasis
 3.67 
 5.93 
Ceapro
 0.00 
 0 
Mymetics
 3.30 
 0.01 
Protokinetix
 0.82 
 0.04 
Statera
 21.74 
 0.03 
Tricida
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Very steady
Out of control
Very steady
Very steady
Very steady
Out of control
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Very High
Below Average
Low
About Average
Very High
Dangerous
Quite High
Below Average
Dangerous
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Not Rated
Not Rated
Current Ratio
1.26
0.55
3.17
2.35
0.38
18.65
0.01
0.54
0.05
N/A
Net Asset
1.12 M
636.41 K
382.08 M
1.91 M
2.27 M
30.53 M
7.63 M
446.23 K
21.17 M
168.51 M
Profit Margin
N/A
N/A
N/A
-1.78
N/A
0.28
N/A
N/A
N/A
N/A
EBITDA
(3.72 M)
631.22 K
(103.2 M)
(2.73 M)
(3.54 M)
4.65 M
(1.96 M)
(2.33 M)
(97.27 M)
(158.52 M)
Current Valuation
12.49 M
660.53 K
82.79 M
15.31 M
6 M
30.26 M
83.16 M
7.5 M
12.92 M
N/A
Price To Book
N/A
4.92
0.79
23.61
53.47
1.7
N/A
20.13
0.16
N/A
Operating Margin
N/A
N/A
-6.01
-1.78
-11.41
0.32
-1.76
N/A
-5.73
N/A
Retained Earnings
N/A
N/A
(206 M)
(37 M)
(18.69 M)
N/A
(81.98 M)
(28.25 M)
N/A
N/A
Current Asset
N/A
N/A
297 M
3 M
874 K
N/A
1.38 M
180 K
N/A
N/A
Beta
0.43
1.55
2.0
-1.2
0.39
1.54
0.24
0.13
N/A
N/A
Number Of Employees
6
11
294
10
23
10
9
7
46
57
Shares Outstanding
51.04 M
41.13 M
55.59 M
901.94 M
79.41 M
78.22 M
303.76 M
316.85 M
54.66 M
N/A
Cash Flow From Operations
(3.22 M)
(693.58 K)
(104.56 M)
(2.44 M)
(3.64 M)
3.51 M
(1.7 M)
(889.89 K)
(28.19 M)
(140.06 M)
Total Debt
4.78 M
227.41 K
18.77 M
77.24 K
401.76 K
2.51 M
162 K
N/A
10.62 M
127.51 M
Return On Equity
N/A
N/A
-0.56
-1.12
N/A
0.18
N/A
-4.03
-2.87
N/A
Z Score
-8.7
6.0
4.2
N/A
-11.5
9.0
-1.4
N/A
-13.2
N/A
Return On Asset
-2.92
-1.07
-0.24
-0.56
-0.81
0.11
-0.14
-2.22
-0.24
N/A
Book Value Per Share
-0.15
0.015
3.0
0.002
-0.034
0.41
-0.21
0.001
-0.2
N/A
Number Of Shares Shorted
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.25 M
N/A
Current Liabilities
N/A
N/A
58 M
N/A
437 K
N/A
51.24 M
40 K
N/A
N/A
Total Asset
1.12 M
636.41 K
382.08 M
1.91 M
2.27 M
30.53 M
7.63 M
446.23 K
21.17 M
168.51 M
Debt To Equity
N/A
4.65
0.52
0.07
0.31
0.08
N/A
31.5
0.23
N/A
Target Price
N/A
N/A
N/A
N/A
0.58
N/A
N/A
N/A
N/A
N/A
Short Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.39
N/A
Shares Owned By Institutions
N/A
N/A
9.8
N/A
N/A
N/A
N/A
0.022
5.41
N/A
Market Capitalization
9.86 M
2.47 M
131.39 M
18.67 M
2.13 M
40.16 M
5.47 M
9.51 M
1.97 M
N/A
Price To Earning
N/A
2.98
-13.64
-3.04
13.82
31.9
-2.4
-9.86
N/A
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
N/A
4.79
11.17
26.52
1.89
12.17
N/A
1.61
N/A
Net Income
(4.92 M)
759.62 K
(114.2 M)
(2.78 M)
(2.96 M)
2.84 M
(4.73 M)
(2.33 M)
(101.88 M)
(176.57 M)
Earnings Per Share
N/A
0.02
-2.95
-0.003
-0.031
0.05
-0.016
-0.009
-0.76
N/A
Shares Owned By Insiders
17.44
10.53
N/A
14.13
2.05
3.92
54.9
30.73
15.93
N/A
Revenue
N/A
N/A
57.29 M
1.56 M
37.73 K
17.2 M
3 K
N/A
1.49 M
N/A
Working Capital
N/A
N/A
239 M
3 M
437 K
N/A
(49.86 M)
140 K
N/A
N/A
Cash And Equivalents
2.19 M
761.6 K
153.13 M
1.74 M
764.97 K
11.37 M
350 K
18.83 K
506.1 K
N/A
Cash Per Share
0.04
0.02
3.37
N/A
0.01
0.14
N/A
N/A
0.01
N/A
Gross Profit
N/A
(1.71 K)
34.18 M
1.56 M
(1.15 M)
9.69 M
(545 K)
N/A
998.72 K
N/A
Day Typical Price
0.005
2.0E-4
2.54
0.0125
1.0E-4
5.83
0.001
0.0094
0.0374
0.027
Accumulation Distribution
N/A
N/A
N/A
N/A
N/A
0.0523
N/A
N/A
0.15
0.23
Market Facilitation Index
N/A
N/A
N/A
N/A
N/A
0.31
N/A
N/A
0.006
0.007
Daily Balance Of Power
(9,223,372,036,855)
0.0
0.0
(9,223,372,036,855)
0.0
0.6774
0.0
9.2 T
(0.05)
0.7143
Period Momentum Indicator
(0.0001)
N/A
N/A
(0)
N/A
0.21
N/A
3.0E-4
(0.0003)
0.005
Rate Of Daily Change
0.98
1.0
1.0
0.83
1.0
1.04
1.0
1.03
0.99
1.22
Day Median Price
0.005
2.0E-4
2.54
0.0125
1.0E-4
5.78
0.001
0.0094
0.038
0.0265
Price Action Indicator
(0.00005)
N/A
N/A
(0)
N/A
0.26
N/A
1.0E-4
(0)
0.004
Coefficient Of Variation
(1,452)
N/A
N/A
(996.94)
N/A
815.9
N/A
2781.55
(1,208)
(400.22)
Mean Deviation
3.22
N/A
N/A
3.09
N/A
123.42
N/A
9.47
7.55
7.99
Jensen Alpha
(0.75)
N/A
N/A
(0.73)
N/A
56.87
N/A
0.8209
(1.04)
(2.59)
Total Risk Alpha
(2.19)
N/A
N/A
(2.18)
N/A
(4.01)
N/A
(1.37)
(2.46)
(4.09)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
8.56
N/A
0.027
N/A
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
52.97
N/A
229.41
N/A
N/A
Standard Deviation
10.94
N/A
N/A
9.39
N/A
509.09
N/A
14.43
11.47
10.73
Kurtosis
22.65
N/A
N/A
31.69
N/A
65.98
N/A
2.47
3.17
3.65
Potential Upside
N/A
N/A
N/A
1.34
N/A
10.53
N/A
25.0
16.13
13.33
Treynor Ratio
8.56
N/A
N/A
0.4341
N/A
1.12
N/A
(0.16)
(1.21)
2.6
Maximum Drawdown
109.39
N/A
N/A
62.53
N/A
4159.06
N/A
84.38
64.44
76.06
Variance
119.65
N/A
N/A
88.26
N/A
259175.76
N/A
208.08
131.63
115.13
Market Risk Adjusted Performance
8.57
N/A
N/A
0.4441
N/A
1.13
N/A
(0.15)
(1.20)
2.61
Risk Adjusted Performance
(0.04)
N/A
N/A
(0.07)
N/A
0.1035
N/A
0.0369
(0.05)
(0.18)
Skewness
0.8691
N/A
N/A
(3.81)
N/A
8.12
N/A
0.39
(0.48)
(0.01)
Semi Deviation
N/A
N/A
N/A
N/A
N/A
0.0
N/A
11.8
N/A
N/A
Information Ratio
(0.08)
N/A
N/A
(0.11)
N/A
0.1223
N/A
0.0284
(0.09)
(0.26)
Value At Risk
(5.56)
N/A
N/A
(5.84)
N/A
(8.37)
N/A
(20.71)
(16.99)
(16.33)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
(248.97)
N/A
(13.54)
N/A
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
7.28
N/A
15.15
N/A
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
(20.73)
N/A
139.35
N/A
N/A

ChitogenX Competition Performance Charts

Five steps to successful analysis of ChitogenX Competition

ChitogenX's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ChitogenX in relation to its competition. ChitogenX's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ChitogenX in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ChitogenX's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ChitogenX, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ChitogenX position

In addition to having ChitogenX in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run SRI Sustainable Growth Thematic Idea Now

SRI Sustainable Growth
SRI Sustainable Growth Theme
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in ChitogenX OTC Stock

ChitogenX financial ratios help investors to determine whether ChitogenX OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ChitogenX with respect to the benefits of owning ChitogenX security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY